C-kit and PDGFRA gene mutations in triple negative breast cancer.

In this study, we evaluated C-kit immunohistochemical expression and C-kit and platelet derived growth factor receptor A (PDGFRA) gene mutations in triple negative breast cancer. 171 cases were analyzed by immunohistochemical staining for the expression of C-kit and 45 cases, including 10 C-kit negative cases and 35 C-kit positive cases, were performed for C-kit gene mutations in exons 9, 11, 13 and 17 and PDGFRA gene mutations in exons 12 and 18. C-kit expression was detected in 42.1% of triple negative breast cancers. Only 1 activating mutation was detected in exon 11 of C-kit gene in 1 case. No activating mutations were found in the other 44 cases. C-kit expression is a frequent finding in triple negative breast cancers; 1 activating mutation which was also found in gastrointestinal stromal tumors was detected; a few cases might benefit from imatinib.

[1]  G. Hortobagyi,et al.  Imatinib mesylate (Gleevec) in advanced breast cancer-expressing C-Kit or PDGFR-beta: clinical activity and biological correlations. , 2008, Annals of oncology : official journal of the European Society for Medical Oncology.

[2]  Markku Miettinen,et al.  KIT (CD117): A Review on Expression in Normal and Neoplastic Tissues, and Mutations and Their Clinicopathologic Correlation , 2005, Applied immunohistochemistry & molecular morphology : AIMM.

[3]  J. Lasota.  Not all c-kit mutations can be corrected by imatinib. , 2007, Laboratory investigation; a journal of technical methods and pathology.

[4]  Susan O'Brien,et al.  Dasatinib in imatinib-resistant Philadelphia chromosome-positive leukemias. , 2006, The New England journal of medicine.

[5]  G. Sauter,et al.  KIT (CD117)-positive breast cancers are infrequent and lack KIT gene mutations. , 2004, Clinical cancer research : an official journal of the American Association for Cancer Research.

[6]  A. AlKushi,et al.  Clinicopathologic features and prognosis of triple-negative breast cancer in patients 40 years of age and younger in Saudi Arabia. , 2012, Hematology/oncology and stem cell therapy.

[7]  C. Antonescu.  Targeted therapies in gastrointestinal stromal tumors. , 2008, Seminars in diagnostic pathology.

[8]  Sung-Bae Kim,et al.  Clinicopathologic significance of the basal-like subtype of breast cancer: a comparison with hormone receptor and Her2/neu-overexpressing phenotypes. , 2006, Human pathology.

[9]  J. Jett,et al.  A phase II trial of imatinib (ST1571) in patients with c-kit expressing relapsed small-cell lung cancer: a CALGB and NCCTG study. , 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

[10]  R. Salgia,et al.  Growth inhibition and modulation of kinase pathways of small cell lung cancer cell lines by the novel tyrosine kinase inhibitor STI 571 , 2000, Oncogene.

[11]  Ping Chen,et al.  Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis , 2014, World Journal of Surgical Oncology.

[12]  J. Dering,et al.  Dasatinib, an orally active small molecule inhibitor of both the src and abl kinases, selectively inhibits growth of basal-type/“triple-negative” breast cancer cell lines growing in vitro , 2007, Breast Cancer Research and Treatment.

[13]  B. Druker,et al.  Inhibition of c-kit receptor tyrosine kinase activity by STI 571, a selective tyrosine kinase inhibitor. , 2000, Blood.

[14]  A. González-Angulo,et al.  Triple‐negative breast cancer in Hispanic patients , 2011, Cancer.

[15]  Ping Yang,et al.  Primary adenoid cystic carcinoma of the lung , 2007, Cancer.

[16]  R. Lai,et al.  Detection of c-KIT and PDGFRA gene mutations in gastrointestinal stromal tumors: comparison of DHPLC and DNA sequencing methods using a single population-based cohort. , 2010, American journal of clinical pathology.

[17]  S. George,et al.  Recent advances in the treatment of gastrointestinal stromal tumors , 2014, Therapeutic advances in medical oncology.

[18]  K. Wakasa,et al.  c‐Kit expression as a prognostic molecular marker in patients with basal‐like breast cancer , 2013, The British journal of surgery.

[19]  Jacques Ferlay,et al.  Estimating the world cancer burden: Globocan 2000 , 2001, International journal of cancer.

[20]  E. Lerma,et al.  Immunohistochemical heterogeneity of breast carcinomas negative for estrogen receptors, progesterone receptors and Her2/neu (basal-like breast carcinomas) , 2007, Modern Pathology.

[21]  Ping Chen,et al.  Discovery of N-(2-chloro-6-methyl- phenyl)-2-(6-(4-(2-hydroxyethyl)- piperazin-1-yl)-2-methylpyrimidin-4- ylamino)thiazole-5-carboxamide (BMS-354825), a dual Src/Abl kinase inhibitor with potent antitumor activity in preclinical assays. , 2004, Journal of medicinal chemistry.

[22]  J. Fletcher,et al.  KIT extracellular and kinase domain mutations in gastrointestinal stromal tumors. , 2000, The American journal of pathology.

[23]  A. Tfayli,et al.  c-Kit expression and mutations in phyllodes tumors of the breast. , 2010, Anticancer research.

[24]  G. Rappa,et al.  Imatinib mesylate enhances the malignant behavior of human breast carcinoma cells , 2011, Cancer Chemotherapy and Pharmacology.